FDA-cleared profile

AutoContour Model RADAC V2

Radformation, Inc. · Radiotherapy Planning Imaging · FDA-cleared (510(k))

Authorized purpose: AutoContour Model RADAC V2 assists radiation treatment planners with reviewed CT and MR contour generation, DICOM RT Structure Set export, and rigid or deformable registration; this release added 58 CT and six MR models.

Clinical role
Initial contour generation and registration support before radiation-treatment planning
Images and patients
Radiotherapy Planning Imaging · Multi-region
Key limitation
Keep in mind: The packet reports no clinical studies and requires users to review every slice and approve structures before export to a treatment-planning system.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: AutoContour Model RADAC V2 assists radiation treatment planners with reviewed CT and MR contour generation, DICOM RT Structure Set export, and rigid or deformable registration; this release added 58 CT and six MR models.
  • Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Multi-region Input: DICOM-compliant CT or MR image data for contouring or registration/fusion; PET/CT input is for registration/fusion only.
  • Who uses it?Intended users: Radiation treatment planners.
  • What does the software produce?Output: DICOM-compliant structure-set data for import into a radiation-therapy treatment-planning system, after user review and modification.
  • What is its most important limitation?Key limitation: The packet reports no clinical studies and requires users to review every slice and approve structures before export to a treatment-planning system.

Clinical takeaway. Clinical role: AutoContour Model RADAC V2 assists radiation treatment planners with reviewed CT and MR contour generation, DICOM RT Structure Set export, and rigid or deformable registration; this release added 58 CT and six MR models.

Evidence takeaway. Evidence from the reviewed source record: Exact FDA summaries document independent held-out testing, DSC criteria stratified by structure size, clinical review, and release-specific regression checks. Independent studies of other AutoContour versions show potential time savings and clinically important failure modes; those studies are product-family context, not validation of each submission.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AutoContour Model RADAC V2 assists radiation treatment planners with reviewed CT and MR contour generation, DICOM RT Structure Set export, and rigid or deformable registration; this release added 58 CT and six MR models.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Initial contour generation and registration support before radiation-treatment planning
  • Exact FDA submission
  • Checked 2026-09-03
Required input
DICOM-compliant CT or MR image data for contouring or registration/fusion; PET/CT input is for registration/fusion only.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description and technology table define the subject-device input boundary.

Output and clinician action
DICOM-compliant structure-set data for import into a radiation-therapy treatment-planning system, after user review and modification.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description supports structure-set output and review/edit workflow, not release-dependent registration objects as output.

Care setting
Radiation-therapy departments in hospitals, clinics, and other qualified treatment-planning facilities.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Radiation treatment planners.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indication names radiation treatment planners and does not establish the broader qualified-professional wording.

Limitations
The packet reports no clinical studies and requires users to review every slice and approve structures before export to a treatment-planning system.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet states both the clinical-study boundary and the required review/approval process.

Evidence summary
Exact FDA summaries document independent held-out testing, DSC criteria stratified by structure size, clinical review, and release-specific regression checks. Independent studies of other AutoContour versions show potential time savings and clinically important failure modes; those studies are product-family context, not validation of each submission.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Exact FDA summaries document independent held-out testing, DSC criteria stratified by structure size, clinical review, and release-specific regression checks. Independent studies of other AutoContour versions show potential time savings and clinically important failure modes; those studies are product-family context, not validation of each submission.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
100%; 95%; 90%; 85%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

Reported specificity
85%; 100%; 90%; 80%
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-13

Values reported in the exact-submission materials. Consult the linked source for endpoint, threshold, population, and confidence interval before comparison.

New CT models

58 models

  • EndpointCT contouring models added versus K200323
  • PopulationAutoContour Model RADAC V2 testing described in K220598
  • Tested versionAutoContour Model RADAC V2

CT mean DSC, large structures

0.94 DSC

  • EndpointMean DSC across large CT structures
  • PopulationAutoContour Model RADAC V2 testing described in K220598
  • Tested versionAutoContour Model RADAC V2

CT mean DSC, medium structures

0.82 DSC

  • EndpointMean DSC across medium CT structures
  • PopulationAutoContour Model RADAC V2 testing described in K220598
  • Tested versionAutoContour Model RADAC V2

CT mean DSC, small structures

0.61 DSC

  • EndpointMean DSC across small CT structures
  • PopulationAutoContour Model RADAC V2 testing described in K220598
  • Tested versionAutoContour Model RADAC V2

Older-version mean contouring time saved

36.6 minutes

  • EndpointMean time saved in the timing subset
  • PopulationAutoContour v1.0.25.0 product-family study
  • Tested versionAutoContour v1.0.25.0

K220598 FDA performance package for AutoContour Model RADAC V2

  • DesignManufacturer nonclinical contour-model validation using held-out or independent images, structure-size DSC criteria, expert review, and release-dependent regression testing
  • PopulationRelease-specific CT or MR structures and image sets described in the FDA summary
  • Scopeexact submission
  • Tested versionAutoContour Model RADAC V2
  • IndependenceSponsor or vendor study

K220598

Manufacturer evidence submitted for substantial equivalence. V2 added MR contouring, 58 CT models, six MR models, automatic deformable registration, and a local automatic-contouring processor while retaining the Windows client and DICOM workflow.

Clinical evaluation of five commercial AI contouring systems

  • DesignIndependent retrospective multi-product evaluation with geometric, qualitative, and timing endpoints
  • Population80 radiotherapy patients and 45 structures
  • Scopeproduct family
  • Tested versionAutoContour v1.0.25.0
  • Samplen=80
  • Sites1
  • IndependenceIndependent study

PMID 37601695

The evaluated software differs from later RADAC submissions; reported efficiency cannot be assumed for another version or site.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K220598 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists. Maintain ongoing FDA and vendor surveillance.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS Radiation Oncology Model material. Evaluate the product within the radiation-therapy planning service line using net staff time after review, plan quality, rework, throughput, implementation cost, and recurring cost.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM-compliant CT or MR image data for contouring or registration/fusion; PET/CT input is for registration/fusion only.

    Scope: Exact FDA submission. The exact device description and technology table define the subject-device input boundary.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K220598: AutoContour Model RADAC V2

  2. Routing

    Source context, not route validation: Windows client and agent components exchange DICOM images and RT Structure Sets with network storage and treatment-planning systems; later releases add rigid or deformable registration and expanded automatic-routing options.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K220598: AutoContour Model RADAC V2 · AutoContour v2.7 product page

  3. AI processing

    Source context, not route validation: The cleared lineage uses a Windows client and local agent with a Linux-based cloud contouring service; V2 materials also describe a local automatic-contouring processor. Confirm the installed architecture, data flow, and model inventory rather than transferring current v2.7 claims to an older release.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K220598: AutoContour Model RADAC V2 · AutoContour v2.7 product page

  4. Returned objects

    Source context, not route validation: DICOM-compliant structure-set data for import into a radiation-therapy treatment-planning system, after user review and modification.

    Scope: Exact FDA submission. The exact device description supports structure-set output and review/edit workflow, not release-dependent registration objects as output.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K220598: AutoContour Model RADAC V2

  5. Viewer/worklist/report

    Unresolved route: DICOM-compliant structure-set data for import into a radiation-therapy treatment-planning system, after user review and modification.

    Scope: Exact FDA submission. The exact device description supports structure-set output and review/edit workflow, not release-dependent registration objects as output.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K220598: AutoContour Model RADAC V2

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The cleared lineage uses a Windows client and local agent with a Linux-based cloud contouring service; V2 materials also describe a local automatic-contouring processor. Confirm the installed architecture, data flow, and model inventory rather than transferring current v2.7 claims to an older release.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Windows client and agent components exchange DICOM images and RT Structure Sets with network storage and treatment-planning systems; later releases add rigid or deformable registration and expanded automatic-routing options.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Current Radformation terms describe anonymization of selected CT or MR planning data, encryption in transit, and deletion after returned processing, while assigning the customer responsibility for preventing PHI disclosure. These current product-family terms must be confirmed against the older installed release and contract.
  • Product family
  • Checked 2026-09-03

Request the current security package and contract controls for the proposed deployment.

Training
Only trained and qualified radiation-therapy professionals should operate the software and review, correct, and approve its outputs. Local onboarding must include release-specific limitations, failure examples, escalation, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

V2 added MR contouring, 58 CT models, six MR models, automatic deformable registration, and a local automatic-contouring processor while retaining the Windows client and DICOM workflow. Procurement should map the installed build, modules, models, anatomies, inputs, and outputs to K220598 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that an earlier cleared release includes them.

Interoperability acceptance

Windows client and agent components exchange DICOM images and RT Structure Sets with network storage and treatment-planning systems; later releases add rigid or deformable registration and expanded automatic-routing options.

exact submission · checked 2026-09-03

Test representative imports, exports, identifiers, orientation, geometry, structure names, units, failure handling, and round trips in the local environment.

Clinical acceptance

Use a signed local test set spanning supported anatomies, scanners, protocols, unusual or postsurgical anatomy, and small or complex structures. Measure edit burden, rejection, downstream plan effects, and reviewer agreement rather than relying only on average overlap metrics.

product family · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model total annual and per-plan cost against hands-on and elapsed time after review, correction, failed transfers, rework, support, upgrades, downtime, and any effect on plan quality or throughput.

product family · checked 2026-09-03

Vendor time-saving results are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact software and model version, anatomy, structure, scanner and protocol, patient position, contrast, unusual or postsurgical anatomy, reviewer role, edit time, rejected outputs, DICOM-transfer failures, downstream plan effects, incidents, recalls, and updates. Revalidate after material workflow or model changes.

product family · checked 2026-09-03

Trend failures and edits by exact software version, model, anatomy, scanner, protocol, and site.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K220598
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiotherapy Planning Imaging
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact technology table states the supported modalities and PET/CT restriction. Controlled directory display reconciled from exact FDA wording: CT or MR for contouring or registration/fusion; PET/CT for registration/fusion only. -> Radiotherapy Planning Imaging.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-08-24
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, peer reviewed publication, health technology guidance, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared release was found. Obtain a written quote separating license basis, sites or users, enabled modules or models, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

12 sources - 3 history items

Source ledger

  1. FDA K220598: AutoContour Model RADAC V2

    U.S. Food and Drug Administration - Published 2022-08-24 - Accessed 2026-09-19

    Scope: purpose, anatomy, modality, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  7. AutoContour v2.7 product page

    Radformation, Inc. - Accessed 2026-09-02

    Scope: productFamily, integration, deployment, pricingResearch, currentCommercialContext, implementationCapabilities

  8. Radformation Software License Agreement and support terms

    Radformation, Inc. - Accessed 2026-09-02

    Scope: security, training, pricing, monitoring, dataGovernance, implementationCapabilities

  9. Artificial intelligence technologies to aid contouring for radiotherapy treatment planning

    National Institute for Health and Care Excellence - Published 2023-09-27 - Accessed 2026-09-02

    Scope: limitations, training, pricing, evidenceSummary, economics, monitoring, implementationCapabilities

  10. A clinical evaluation of the performance of five commercial artificial intelligence contouring systems for radiotherapy

    Frontiers in Oncology - Published 2023-08-08 - Accessed 2026-09-02

    Scope: evidenceSummary, evidenceStudy, evidenceMetrics, economics, implementationCapabilities

  11. Evaluation of multiple-vendor AI autocontouring solutions

    Radiation Oncology - Published 2024-05-31 - Accessed 2026-09-02

    Scope: evidenceSummary, evidenceStudy, evidenceMetrics, implementationCapabilities

  12. Evaluation and failure analysis of four commercial deep learning-based autosegmentation software for abdominal organs at risk

    Journal of Applied Clinical Medical Physics - Published 2025-02-13 - Accessed 2026-09-02

    Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, monitoring, implementationCapabilities

Research history

  1. K220598 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260509

AutoContour (RADAC V5)

Radformation, Inc.

Authorized purpose: AutoContour Model RADAC V5 assists radiation treatment planners with contouring and reviewing structures in medical images for radiation therapy treatment planning. It produces initial machine-learning contours for user review and modification; it does not independently approve a contour or treatment plan.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-03-19
FDA-cleared K252188

EMLA (Elekta Evo); EMLA (VersaHD); EMLA (Elekta Harmony Pro); EMLA (Elekta Infintiy); EMLA (Elekta Harmony); EMLA (Elekta Synergy)

Elekta Solutions AB

Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2026-01-15
FDA-cleared K253091

ART-Plan+ (v3.1.0)

Therapanacea Sas

Authorized purpose: ART-Plan+ assists trained radiation-therapy professionals with multimodal image review, registration, contouring, and the release-specific planning functions described in K253091. This release combined Annotate, prostate SmartPlan, and AdaptBox for supported head-and-neck, breast or thorax, and male-pelvis offline adaptive workflows, and added structures without changing the core indication.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K242748

Oncospace

Oncospace, Inc.

Authorized purpose: Oncospace supports trained radiation therapy professionals with protocol configuration, machine-learning achievable-dose prediction, planning-objective exchange, and plan review across head-and-neck, thoracic, abdominal, and pelvic workflows using locked models.

Modality
Radiotherapy Planning Imaging
Anatomy
Multi-region
Decision
2025-04-11

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history